Trial Profile

Preoperative Window of Opportunity Study with Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative & Ki67≥10% Early Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Giredestrant (Primary) ; Tamoxifen
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms EMPRESS

20 Oct 2025 Primary endpoint has been met. (Change in proliferative index (Ki67 expression))
20 Oct 2025 Results presented in the MEDSIR Media Release
07 Feb 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com